Results 111 to 120 of about 7,099 (210)

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

Journal of Hepatology, 2018
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes. In 48-week results from two ongoing, double-blind, randomized phase III trials, TAF was non-inferior to
Agarwal, Kosh, Brunetto, Maurizia, Seto, Wai Kay, Lim, Young-Suk, Fung, Scott, Marcellin, Patrick, Ahn, Sang Hoon, Izumi, Namiki, Chuang, Wan–Long, Bae, Ho, Sharma, Manoj, Janssen, Harry L. A., Pan, Calvin Q., Çelen, Mustafa Kemal, Furusyo, Norihiro, Shalimar, Dr, Yoon, Ki Tae, Trinh, Huy, Flaherty, John F., Gaggar, Anuj, Lau, Audrey H., Cathcart, Andrea L., Lin, Lanjia, Bhardwaj, Neeru, Suri, Vithika, Mani Subramanian, G., Gane, Edward J., Buti, Maria, Chan, Henry L. Y.   +28 more
openaire   +5 more sources

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Health Science Reports
Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences.
Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke   +4 more
doaj   +1 more source

Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives

Life
Body weight is impacted by several individual host and environmental factors. In a person living with HIV (PLWH), weight is also influenced by the disease stage.
Konstantinos Markakis, Olga Tsachouridou, Eleni Georgianou, Dimitrios Pilalas, Sideris Nanoudis, Symeon Metallidis   +5 more
doaj   +1 more source

Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines [PDF]

, 2019
[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) initiation for all HIV-infected individuals regardless of CD4 count.
Balboa Barreiro, Vanesa, Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Margusino-Framiñán, Luis, Martín-Herranz, Isabel, Mena, Álvaro, Pernas, Berta, Poveda, Eva   +7 more
core   +1 more source

Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <=50 copies/ml: does eGFR matter? [PDF]

, 2020
Our aim was to evaluate the association between most recent eGFR values and the risk of switching from TDF to TAF or to dual therapy (DT) separately for the two strategies in a real-life setting.
A Cozzi-Lepri on behalf of the Icona Foundation Study Network, Antinori, A, Biagio, AD, Cascio, A, De Vito, A, Gagliardini, R, Gianotti, N, Gori, A, Lichtner, M, Monforte, AD, Saracino, A, Vergori, A   +11 more
core  

Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks [PDF]

Atherosclerosis; Cardiovascular disease; Chronic hepatitis BAterosclerosi; Malaltia cardiovascular; Hepatitis B crònicaAterosclerosis; Enfermedad cardiovascular; Hepatitis B crónicaBackground Patients with chronic hepatitis B (CHB) who switch from ...
Ahn, Sang-Hoon, Buti Ferret, Maria, Chen, Chi-Yi, Fung, Scott, Pan, Calvin Q., Seto, Wai-Kay, Wong, Grace Lai-Hung   +6 more
core   +1 more source

Tenofovir alafenamide/tenofovir disoproxil fumarate

Reactions Weekly, 2021
openaire   +1 more source

Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort

International Journal of Infectious Diseases
Objectives: Long-term effects of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on hepatic, renal, and metabolic parameters remain poorly characterized, especially in people with HIV (PWH) and hepatitis B virus ...
Mariacristina Poliseno, Sergio Lo Caputo, Alessandro Tavelli, Roberta Gagliardini, Lidia Gazzola, Annalisa Saracino, Teresa Antonia Santantonio, Nicola Squillace, Massimo Puoti, Valentina Mazzotta, Adndrea Antinori, Antonella d’Arminio Monforte, Alessandro Cozzi-Lepri   +12 more
doaj   +1 more source

Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years. [PDF]

BACKGROUND: Both tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are the first-line treatments for chronic hepatitis B (CHB). We have showed switching from TDF to TAF for 96 weeks resulted in further alanine aminotransferase (ALT ...
Bui, Delana, Hu, Ke-Qin, Huynh, Tung, Zhou, Tina   +3 more
core   +1 more source